摘要
目的 :探讨来源于HER2 /neu原癌蛋白的多肽诱导特异性细胞免疫应答及其在体内的抗癌效应。方法 :利用合成的2个具有小鼠H 2Kd 分子结合基序的HER2 /neu肽作为肿瘤排斥抗原 ,在体外刺激小鼠脾淋巴细胞以及皮下免疫小鼠 ,观察淋巴细胞的增殖能力、CTL的杀伤活性以及HER2 /neu肽的抑瘤作用。结果 :HER2 /neu肽在体内和体外对BALB/c小鼠淋巴细胞的增殖都有明显的促进作用。HER2 /neu肽免疫BALB/c小鼠后 ,可以从小鼠淋巴细胞中诱导出肽特异性CTL ,这些CTL可以特异地杀伤HER2 /neu阳性SP2 / 0细胞 ,而对HER2 /neu阴性SP2 / 0细胞却无明显的杀伤活性。SP2 / 0HER2细胞在HER2 /neu肽免疫小鼠体内的生长受到抑制。结论 :研究结果表明HER2 /neu肽可以起到一定的抑瘤保护作用 ,提示 ,肿瘤特异性抗原来源的MHC Ⅰ类分子肽表位作为疫苗进行肿瘤免疫治疗是可行的。
Objective: To study the cellular immune responses and the anti tumor effects induced by peptides derived from onco protein HER2/neu. Methods: Two HER2/neu peptides compatible with H 2K d binding motif as tumor rejection antigens were synthesized. The ability of inducing peptide specific CTLs and suppressing the tumor growth in BALB/c mice immunized by HER2/neu peptide was analyzed. Results: HER2/neu peptides could promote the proliferation of BALB/c lymphocytes both in vitro and in vivo. HER2/neu peptide specific CTLs could be induced from peptide immunized BALB/c mice, which showed specifically killing effects on HER2/neu positive SP2/0HER2 cells but not on HER2/neu negative SP2/0 cells. Moreover, the growth of SP2/0HER2 tumor were significantly suppressed in BALB/c mice immunized with HER2/neu peptides. Conclusion: These results suggested that it was feasible to use MHC Ⅰ epitopes derived from tumor specific antigens as vaccines for cancer immunotherapy.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2000年第4期243-246,共4页
Chinese Journal of Cancer Biotherapy
基金
军事医学科学院创新基金课题
